# Efficacy of Carbocisteine in Reducing Exacerbations in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

## TL;DR

Carbocisteine reduces COPD flare-ups and is safe, making it a useful and affordable treatment option for patients with frequent symptoms.

## Contribution

This study provides the first systematic review and meta-analysis confirming carbocisteine's efficacy in reducing COPD exacerbations.

## Key findings

- Carbocisteine significantly reduced annual COPD exacerbation rates compared to placebo.
- Carbocisteine showed a safety profile similar to placebo with minimal adverse events.
- The drug improves mucociliary clearance and reduces airway inflammation and oxidative stress.

## Abstract

What are the main findings?
Carbocisteine lowered the rate of COPD exacerbations, supporting its use as an additional treatment to improve disease control.Carbocisteine was well tolerated, showing a safety profile similar to placebo with only mild side effects reported.

Carbocisteine lowered the rate of COPD exacerbations, supporting its use as an additional treatment to improve disease control.

Carbocisteine was well tolerated, showing a safety profile similar to placebo with only mild side effects reported.

What are the implications of the main findings?
Carbocisteine may be a useful add-on therapy for COPD patients who experience frequent exacerbations or have excess mucus, helping to improve symptom control and reduce flare-ups.Its good safety and low cost make carbocisteine a practical option, especially in resource-limited settings or for patients who cannot access or tolerate other advanced COPD treatments.

Carbocisteine may be a useful add-on therapy for COPD patients who experience frequent exacerbations or have excess mucus, helping to improve symptom control and reduce flare-ups.

Its good safety and low cost make carbocisteine a practical option, especially in resource-limited settings or for patients who cannot access or tolerate other advanced COPD treatments.

This systematic review and meta-analysis aimed to evaluate the efficacy and safety of carbocisteine in reducing chronic obstructive pulmonary disease (COPD) exacerbations based on evidence from randomized controlled trials (RCTs). A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. RCTs comparing carbocisteine (1500 mg/day) with placebo in COPD patients, with a minimum follow-up of six months, were included. Data on exacerbation rates and adverse events were extracted and analyzed using a random-effects model. Four RCTs involving 1746 patients met inclusion criteria. Pooled analysis showed that carbocisteine significantly reduced the annual rate of acute exacerbations compared to placebo (WMD = −0.40; 95% CI: −0.69 to −0.11), with no significant increase in adverse events (OR = 1.02; 95% CI: 0.76 to 1.37). Mechanistically, carbocisteine improves mucociliary clearance, suppresses airway inflammation, reduces oxidative stress, and may hinder bacterial colonization. Carbocisteine is associated with a significant reduction in COPD exacerbations and demonstrates a favorable safety profile. It may serve as an effective adjunctive therapy in patients with frequent exacerbations and mucus hypersecretion.